Courtney Flaherty

Articles

FDA Grants Priority Review to Repotrectinib for NTRK+ Solid Tumors

February 14th 2024

Repotrectinib is under priority review for patients with NTRK-positive locally advanced or metastatic solid tumors and high unmet medical need.

Recent Approvals Across Hematologic Malignancies Usher in a New Era

February 14th 2024

Mikkael A. Sekeres, MD, MS, highlights recent approvals and emerging therapeutics in hematologic malignancies discussed by his colleagues.

McAndrew Expands on the Evolving Treatment Armamentarium in HER2+ Breast Cancer

February 13th 2024

Nicholas P. McAndrew, MD, MSCE, discusses how updated clinical trial findings are shifting the treatment paradigm in HER2-positive metastatic breast cancer.

Emavusertib Demonstrates Safety, Early Antitumor Activity in Select Patients With FLT3-Mutant R/R AML

February 12th 2024

Alice Mims, MD, discusses the toxicity profile and initial efficacy of emavusertib in heavily pretreated, FLT3-mutated relapsed/refractory AML.

Addressing Patient-Provider Communication Challenges is Vital for Improved Breast Cancer Care

February 9th 2024

Jane L. Meisel, MD, highlighted patient-reported gaps in provider communication regarding treatment-related toxicities in metastatic breast cancer.

FDA Grants Orphan Drug Designation to Soquelitinib in T-Cell Lymphoma

February 9th 2024

Soquelitinib has been granted an orphan drug designation by the FDA for potential use in T-cell lymphoma.

Complementary NGS Improves dMMR Detection With IHC in CRC and Endometrial Cancer

February 8th 2024

Amin Nassar, MD, and Elias Bou Farhat, MD, spotlight a study evaluating the accuracy and sensitivity of NGS mutation signature in assessing MMR status vs IHC testing.

Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization

February 7th 2024

Identifying biomarkers and the mechanism of action of antibody-drug conjugates may optimize benefits with these agents in non–small cell lung cancer.

SOC Role of Frontline Nivolumab Plus Cabozantinib in Metastatic RCC Confirmed With Long-Term Efficacy Results

February 5th 2024

Frontline nivolumab plus cabozantinib continued to demonstrate long-term efficacy and safety vs sunitinib in patients with untreated RCC.

Masofaniten Plus Enzalutamide Shows Safety With Potentially Durable PSA Decreases in mCRPC

February 5th 2024

Christos Kyriakopoulos, MD, discusses key phase 1 results from the ongoing evaluation of masofaniten and enzalutamide in patients with mCRPC.

Pirtobrutinib Continues to Show Safety, Activity in Covalent BTK Inhibitor–Pretreated R/R MCL

February 2nd 2024

Jonathon B. Cohen, MD, MS, expands on updated data from the BRUIN trial of pirtobrutinib in patients with relapsed BTK-exposed mantle cell lymphoma.

Updated CheckMate 649 Data Reinforce Nivolumab Plus Chemo as Frontline SOC in Advanced Gastric Cancers

February 1st 2024

Kohei Shitara, MD, discusses 4-year survival data of chemotherapy plus nivolumab in advanced gastric/GEJ cancer or esophageal adenocarcinoma.

Garmezy Highlights Ongoing and Future Research Directions Across RCC Subtypes

January 31st 2024

Benjamin Garmezy, MD, provides an overview of recent data on immuno-oncology/TKI combination data in variant renal cell carcinoma.

ELAINE-3 Trial Sets Out to Confirm Clinical Benefit of Lasofoxifene/Abemaciclib in ESR1-Mutant, ER+ Breast Cancer

January 30th 2024

Seth A. Wander, MD, PhD, discusses key findings with lasofoxifene from ELAINE-1 and ELAINE-2 that supported the initiation of the ELAINE-3 trial.

Hobbs Highlights Key Research in Hematologic Malignancies at the 2023 ASH Annual Meeting

January 30th 2024

Gabriela Hobbs, MD, discusses the significance of key research across myeloproliferative neoplasms from the 2023 ASH Annual Meeting.

EMA Validates Application for First-Line Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

January 30th 2024

The type II variation application for enfortumab vedotin plus pembrolizumab in untreated metastatic urothelial cancer has been validated by the EMA.

Biomarker Identification Drives Research and Drug Development in NSCLC and SCLC

January 29th 2024

Ranee Mehra, MD, and colleagues detail treatment updates across lung cancer subtypes, including navigating the array of available ALK inhibitors in NSCLC.

CA-125 KELIM Score May Predict Efficacy in Patients With Epithelial Ovarian Cancer Receiving HIPEC During Surgery

January 26th 2024

Gabriella Smith, MD, discusses the potential impact of CA-125 KELIM score for patients with epithelial ovarian cancer undergoing HIPEC during surgery.

Post-Hoc Analysis Confirms Consistent Clinical Benefit With Olaparib Plus Abiraterone in HRR-Mutated mCRPC

January 25th 2024

Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.

Individualized Approach Best Informs Choice of Frontline Immunotherapy or Targeted Therapy Combinations Across RCC Histologies

January 24th 2024

Benjamin Garmezy, MD, discusses challenges associated with navigating the current frontline armamentarium in both clear cell and variant RCC, the impact of frontline IO doublets and IO/TKI regimens on patient outcomes, and the importance of ongoing combination studies for patients with variant RCC.